298 related articles for article (PubMed ID: 23028796)
1. The erythropoietin/erythropoietin receptor signaling pathway promotes growth and invasion abilities in human renal carcinoma cells.
Wu P; Zhang N; Wang X; Zhang C; Li T; Ning X; Gong K
PLoS One; 2012; 7(9):e45122. PubMed ID: 23028796
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions.
Miyake M; Goodison S; Lawton A; Zhang G; Gomes-Giacoia E; Rosser CJ
J Hematol Oncol; 2013 Sep; 6():65. PubMed ID: 24004818
[TBL] [Abstract][Full Text] [Related]
3. EPO-independent functional EPO receptor in breast cancer enhances estrogen receptor activity and promotes cell proliferation.
Reinbothe S; Larsson AM; Vaapil M; Wigerup C; Sun J; Jögi A; Neumann D; Rönnstrand L; Påhlman S
Biochem Biophys Res Commun; 2014 Feb; 445(1):163-9. PubMed ID: 24502950
[TBL] [Abstract][Full Text] [Related]
4. The tumor promoting roles of erythropoietin/erythropoietin receptor signaling pathway in gastric cancer.
Hu W; Zhang Y; Jiang Z; Wang L; Li J; Chen S; Dai N; Si J
Tumour Biol; 2016 Aug; 37(8):11523-33. PubMed ID: 27086036
[TBL] [Abstract][Full Text] [Related]
5. Functional significance of erythropoietin in renal cell carcinoma.
Morais C; Johnson DW; Vesey DA; Gobe GC
BMC Cancer; 2013 Jan; 13():14. PubMed ID: 23305401
[TBL] [Abstract][Full Text] [Related]
6. RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells.
Paragh G; Kumar SM; Rakosy Z; Choi SC; Xu X; Acs G
Am J Pathol; 2009 Apr; 174(4):1504-14. PubMed ID: 19264915
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietin drives breast cancer progression by activation of its receptor EPOR.
Chan KK; Matchett KB; Coulter JA; Yuen HF; McCrudden CM; Zhang SD; Irwin GW; Davidson MA; Rülicke T; Schober S; Hengst L; Jaekel H; Platt-Higgins A; Rudland PS; Mills KI; Maxwell P; El-Tanani M; Lappin TR
Oncotarget; 2017 Jun; 8(24):38251-38263. PubMed ID: 28418910
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin receptor contributes to melanoma cell survival in vivo.
Kumar SM; Zhang G; Bastian BC; Arcasoy MO; Karande P; Pushparajan A; Acs G; Xu X
Oncogene; 2012 Mar; 31(13):1649-60. PubMed ID: 21860424
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma.
Lai SY; Childs EE; Xi S; Coppelli FM; Gooding WE; Wells A; Ferris RL; Grandis JR
Oncogene; 2005 Jun; 24(27):4442-9. PubMed ID: 15856028
[TBL] [Abstract][Full Text] [Related]
10. Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
Gao Y; Li J; Qiao N; Meng Q; Zhang M; Wang X; Jia J; Yang S; Qu C; Li W; Wang D
Oncotarget; 2016 Sep; 7(39):63374-63387. PubMed ID: 27556517
[TBL] [Abstract][Full Text] [Related]
11. Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma.
Lee YS; Vortmeyer AO; Lubensky IA; Vogel TW; Ikejiri B; Ferlicot S; Benoît G; Giraud S; Oldfield EH; Linehan WM; Teh BT; Richard S; Zhuang Z
Clin Cancer Res; 2005 Feb; 11(3):1059-64. PubMed ID: 15709172
[TBL] [Abstract][Full Text] [Related]
12. No erythropoietin-induced growth is observed in non-small cell lung cancer cells.
Frille A; Leithner K; Olschewski A; Olschewski H; Wohlkönig C; Hrzenjak A
Int J Oncol; 2018 Feb; 52(2):518-526. PubMed ID: 29345289
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin reduces cisplatin-induced apoptosis in renal carcinoma cells via a PKC dependent pathway.
Li J; Vesey DA; Johnson DW; Gobe G
Cancer Biol Ther; 2007 Dec; 6(12):1944-50. PubMed ID: 18075299
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro.
Våtsveen TK; Sponaas AM; Tian E; Zhang Q; Misund K; Sundan A; Børset M; Waage A; Brede G
J Hematol Oncol; 2016 Aug; 9(1):75. PubMed ID: 27581518
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma.
Mohyeldin A; Lu H; Dalgard C; Lai SY; Cohen N; Acs G; Verma A
Neoplasia; 2005 May; 7(5):537-43. PubMed ID: 15967106
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression.
Acs G; Zhang PJ; McGrath CM; Acs P; McBroom J; Mohyeldin A; Liu S; Lu H; Verma A
Am J Pathol; 2003 Jun; 162(6):1789-806. PubMed ID: 12759237
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin ameliorates early brain injury after subarachnoid haemorrhage by modulating microglia polarization via the EPOR/JAK2-STAT3 pathway.
Wei S; Luo C; Yu S; Gao J; Liu C; Wei Z; Zhang Z; Wei L; Yi B
Exp Cell Res; 2017 Dec; 361(2):342-352. PubMed ID: 29102603
[TBL] [Abstract][Full Text] [Related]
19. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.
Su SC; Hu X; Kenney PA; Merrill MM; Babaian KN; Zhang XY; Maity T; Yang SF; Lin X; Wood CG
Clin Cancer Res; 2013 Dec; 19(23):6461-72. PubMed ID: 24122794
[TBL] [Abstract][Full Text] [Related]
20. Targeting the erythropoietin receptor on glioma cells reduces tumour growth.
Pérès EA; Valable S; Guillamo JS; Marteau L; Bernaudin JF; Roussel S; Lechapt-Zalcman E; Bernaudin M; Petit E
Exp Cell Res; 2011 Oct; 317(16):2321-32. PubMed ID: 21749867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
